{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:27:40Z","timestamp":1787664460035,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.neuropharm.2013.08.033","type":"journal-article","created":{"date-parts":[[2013,9,8]],"date-time":"2013-09-08T09:46:00Z","timestamp":1378633560000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"PA","title":["Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus"],"prefix":"10.1016","volume":"76","author":[{"given":"Tonya N.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn P.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.08.033_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1750-3639.2005.tb00097.x","article-title":"Profound cardiac sympathetic denervation occurs in Parkinson disease","volume":"15","author":"Amino","year":"2005","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.841304","article-title":"Norepinephrine-dopamine interactions and behavior","volume":"195","author":"Antelman","year":"1977","journal-title":"Science"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2013.08.033_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-002-1301-4","article-title":"Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)","volume":"249","author":"Braak","year":"2002","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.neuropharm.2013.08.033_bib5","doi-asserted-by":"crossref","first-page":"1712.e9","DOI":"10.1016\/j.neurobiolaging.2012.12.020","article-title":"Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease","volume":"34","author":"Brighina","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","article-title":"Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine","volume":"115","author":"Burke","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0161-813X(03)00090-1","article-title":"Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases","volume":"25","author":"Burke","year":"2004","journal-title":"NeuroToxicology"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tins.2008.02.010","article-title":"Altered vesicular dopamine storage in Parkinson's disease: a premature demise","volume":"31","author":"Caudle","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/toxsci\/kfl018","article-title":"Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity","volume":"92","author":"Caudle","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib10","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1523\/JNEUROSCI.0319-07.2007","article-title":"Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration","volume":"27","author":"Caudle","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/cne.902870307","article-title":"Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression","volume":"287","author":"Chan-Palay","year":"1989","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib12","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/j.1460-9568.2006.05143.x","article-title":"Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease","volume":"24","author":"Colebrooke","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib13","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/exnr.1998.6776","article-title":"Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease","volume":"150","author":"Corrigan","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib15","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.neurobiolaging.2007.04.003","article-title":"Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging","volume":"29","author":"Cruz-Muros","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib16","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1523\/JNEUROSCI.14-04-02260.1994","article-title":"Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress","volume":"14","author":"Cubells","year":"1994","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib17","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1007\/BF02940065","article-title":"Imaging of myocardial sympathetic innervation with metaiodobenzylguanidine","volume":"1","author":"Dae","year":"1994","journal-title":"J.\u00a0Nucl. Cardiol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neuropharm.2013.08.033_bib19","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/jnnp-2011-301817","article-title":"Dysfunction of the locus coeruleus\u2013norepinephrine system and related circuitry in Parkinson's disease-related dementia","volume":"84","author":"Del Tredici","year":"2012","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00005072-199603000-00001","article-title":"Neuropathology of Parkinson's disease","volume":"55","author":"Forno","year":"1996","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1749-6632.1992.tb24523.x","article-title":"Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D25k\u2014containing cells","volume":"648","author":"German","year":"1992","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0149-7634(00)00028-2","article-title":"The role of the locus coeruleus in the development of Parkinson's disease","volume":"24","author":"Gesi","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/hmg\/ddi445","article-title":"Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women","volume":"15","author":"Glatt","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(03)00555-6","article-title":"Dysautonomia in Parkinson's disease: neurocardiological abnormalities","volume":"2","author":"Goldstein","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib25","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1172\/JCI45803","article-title":"Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases","volume":"121","author":"Goldstein","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10286-007-0396-1","article-title":"Cardiac sympathetic denervation preceding motor signs in Parkinson disease","volume":"17","author":"Goldstein","year":"2007","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2010.03246.x","article-title":"Catechols in post-mortem brain of patients with Parkinson disease","volume":"18","author":"Goldstein","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2013.08.033_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jnc.12345","article-title":"Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson disease","volume":"126","author":"Goldstein","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib29","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/j.1471-4159.2008.05568.x","article-title":"Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis","volume":"106","author":"Guillot","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib30","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease","volume":"510","author":"Halliday","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.neuro.2012.08.002","article-title":"Association between polychlorinated biphenyls\u00a0and Parkinson's disease neuropathology","volume":"33","author":"Hatcher-Martin","year":"2012","journal-title":"NeuroToxicology"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0378-4347(93)E0430-X","article-title":"Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection","volume":"653","author":"Holmes","year":"1994","journal-title":"J.\u00a0Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0047-6374(83)90100-8","article-title":"The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system","volume":"23","author":"Mann","year":"1983","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/nbdi.2002.0507","article-title":"Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat","volume":"10","author":"McCormack","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1006\/exnr.1998.7008","article-title":"Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease","volume":"156","author":"Miller","year":"1999","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ana.410410417","article-title":"Immunochemical analysis of dopamine transporter protein in Parkinson's disease","volume":"41","author":"Miller","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib36","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/MCB.21.16.5321-5331.2001","article-title":"Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism","volume":"21","author":"Mooslehner","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and \u03b1-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1176\/appi.neuropsych.13.2.222","article-title":"In\u00a0vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease","volume":"13","author":"Murai","year":"2001","journal-title":"J.\u00a0Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","article-title":"The neuropathologic basis of different clinical subgroups of Parkinsons-disease","volume":"50","author":"Paulus","year":"1991","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib60","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib61","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0161-813X(02)00037-2","article-title":"L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice","volume":"23","author":"Reveron","year":"2002","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib40","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bcp.2007.01.036","article-title":"Norepinephrine: the redheaded stepchild of Parkinson's disease","volume":"74","author":"Rommelfanger","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib41","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/msj.20303","article-title":"Mitochondrial pathology in Parkinson's disease","volume":"78","author":"Schapira","year":"2011","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib42","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1523\/JNEUROSCI.6486-11.2012","article-title":"CNS dopamine transmission mediated by noradrenergic innervation","volume":"32","author":"Smith","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2202-2-11","article-title":"Deletion of the alpha-synuclein locus in a subpopulation of C57BL\/6J inbred mice","volume":"2","author":"Specht","year":"2001","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib44","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1201-1280","article-title":"[alpha]-synuclein and cytosolic dopamine: stabilizing a bad situation","volume":"7","author":"Sulzer","year":"2001","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2013.08.033_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mds.25187","article-title":"Neuronal vulnerability, pathogenesis, and Parkinson's disease","volume":"28","author":"Sulzer","year":"2012","journal-title":"Move. Disord."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03033289","article-title":"Intraneuronal dopamine-quinone synthesis: a review","volume":"1","author":"Sulzer","year":"1999","journal-title":"Neurotoxicity Res."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neuron.2009.04.010","article-title":"A\u00a0lethal convergence of dopamine and calcium","volume":"62","author":"Surmeier","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.conb.2005.05.007","article-title":"Autonomous pacemakers in the basal ganglia: who needs excitatory synapses anyway?","volume":"15","author":"Surmeier","year":"2005","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib49","doi-asserted-by":"crossref","first-page":"9938","DOI":"10.1073\/pnas.94.18.9938","article-title":"VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP\u2009toxicity","volume":"94","author":"Takahashi","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib50","first-page":"124165","article-title":"VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease","volume":"2011","author":"Taylor","year":"2011","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib51","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1523\/JNEUROSCI.1495-09.2009","article-title":"Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity","volume":"29","author":"Taylor","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib52","first-page":"427","article-title":"[3H]nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding","volume":"260","author":"Tejani-Butt","year":"1992","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib53","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1096\/fj.00-0205rev","article-title":"The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins","volume":"14","author":"Uhl","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib54","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.05.012","article-title":"Dysregulated dopamine storage increases the vulnerability to \u03b1-synuclein in nigral neurons","volume":"47","author":"Ulusoy","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib55","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.parkreldis.2011.04.016","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis","volume":"17","author":"Velseboer","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib56","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0896-6273(00)80419-5","article-title":"Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine","volume":"19","author":"Wang","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2013.08.033_bib57","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ar.1092310411","article-title":"Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator","volume":"231","author":"West","year":"1991","journal-title":"Anat. Rec."},{"key":"10.1016\/j.neuropharm.2013.08.033_bib58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archneur.60.3.337","article-title":"Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases","volume":"60","author":"Zarow","year":"2003","journal-title":"Arch. Neurol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813004000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T12:32:00Z","timestamp":1563885120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813004000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":61,"alternative-id":["S0028390813004000"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.033","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}